

RESEARCH ARTICLE

Open Access

Serum sodium based modification of the MELD does not improve prediction of outcome in acute liver failure

Paul Manka¹, Lars P Bechmann¹, Frank Tacke², Jan-Peter Sowa¹, Martin Schlattjan¹, Julia Kälsch¹, Christoph Jochum¹, Andreas Paul³, Fuat H Saner³, Christian Trautwein², Guido Gerken¹ and Ali Canbay^{1*}

Abstract

Background: Acute liver failure (ALF) is a devastating clinical syndrome with a high mortality rate. The MELD score has been implied as a prognostic tool in ALF. Hyponatremia is associated with lethal outcome in ALF. Inclusion of serum sodium (Na) into the MELD score was found to improve its predictive value in cirrhotic patients. Therefore the aim of this study was to determine whether inclusion of serum Na improves the predictive value of MELD in ALF compared to established criteria.

Methods: In a prospective single center study (11/2006–12/2010), we recruited 108 consecutive ALF patients (64% females / 36% males), who met the criteria defined by the “Acute Liver Failure Study Group Germany”. Upon admission, clinical and laboratory data were collected, King’s College Criteria (KCC), Model of End Stage Liver Disease score (MELD), and serum sodium based modifications like the MELD-Na score and the United Kingdom Model of End Stage Liver Disease score (UKELD) were calculated and area under the receiver operating characteristic curve analyses were performed regarding the prediction of spontaneous recovery (SR) or non-spontaneous recovery (NSR; death or transplantation).

Results: Serum bilirubin was of no prognostic value in ALF, and Na also failed to predict NSR in ALF. The classical MELD score was superior to sodium-based modifications and KCC.

Conclusions: We validated the prognostic value of MELD-Na and UKELD in ALF. Classic MELD score calculations performed superior to KCC in the prediction of NSR. Serum Na and Na-based modifications of MELD did not further improve its prognostic value.

Keywords: ALF, MELD, MELD-Na, UKELD, Sodium

Background

Acute liver failure (ALF) is a potentially lethal clinical syndrome with a high mortality rate. Nonetheless, immediate intensive care, specific therapies and liver transplantation (LTx) have improved the prognosis of ALF patients significantly [1-3]. According to the European Liver Transplant registry, approximately nine percent of LTx were related to ALF [4]. King’s college (KCC) and Clichy criteria are etiology specific, prognosis predicting allocation tools to warrant timely transplantation and

fair organ distribution [5,6]. However, their accuracy to reliably predict patients’ individual prognosis and to discriminate those patients who will survive without LTx remains a major challenge [7,8].

The model of end-stage liver disease (MELD), initially established to predict survival following transjugular intrahepatic portosystemic shunt (TIPS) procedure and later as an allocation tool for patients with cirrhosis, has been implied as a prognostic tool in ALF and was proven to be superior to the KCC and Clichy criteria [9-11]. Recently, various modifications of the MELD have been introduced and improved accuracy in both, chronic liver failure and ALF [12,13]. Since hepatic encephalopathy (HE) is associated with a fulminant course of ALF and a

* Correspondence: Ali.canbay@uni-due.de

¹Department of Gastroenterology and Hepatology, University Hospital, University Duisburg-Essen, Hufelandstr 55, 45122, Essen, Germany
Full list of author information is available at the end of the article

decrease in extracellular fluid osmolality is associated with an increase in brain swelling, factors that modulate fluid osmolality were taken into account as prognostic markers [14,15]. Patients with serum sodium between 145 and 150 mmol/l are known to have fewer episodes of intracranial hypertension and consequently a higher risk to develop brain edema. Thus, hyponatremia might worsen the prognosis in ALF [16]. As hyponatremia is associated with poor prognosis in cirrhosis, inclusion of serum sodium (Na) into the MELD was found to improve its predictive value in chronic liver diseases [13,17]. Two sodium containing MELD modifications, "UKELD" and "MELD-Na", were proposed to enhance its prognostic ability in chronic liver failure [18,19]. A potential predictive value of these modifications in ALF has not been evaluated yet.

The aim of this study was to determine whether inclusion of serum sodium into the MELD score improves its predictive value in ALF, compared to established criteria. By evaluating these tools in a large prospective single-center study with ALF patients, we demonstrate that the sodium based MELD modifications do not improve the prognostic value of the standard MELD formula.

Methods

Patients and ethical considerations

The study was carried out according to the Declaration of Helsinki and the guidelines of the International Conference for Harmonization for Good Clinical Practice, it was approved by the local Ethics Committee of the University Hospital Essen (Institutional Review Board). In a prospective monocenter study (11/2006–12/2010), we recruited 108 consecutive ALF patients (64% females / 36% males), who met the criteria defined by the "Acute Liver Failure Study Group Germany" [20]. In brief, ALF was diagnosed by significant liver dysfunction with pathologically increased laboratory parameters (bilirubin, AST, ALT, AP, γ -GT) and an international normalized ratio (INR) of >1.5 with the concomitant presence of any degree of encephalopathy. Reference values for normal ranges are presented in Table 1. A pathological increase was defined as any value above these ranges. Other causes of liver dysfunction were excluded, such as acute-on-chronic liver failure or pre-existing cirrhosis. All patients had presented within four weeks of disease onset without pre-existing liver disease. Upon admission, clinical data were collected. Outcome (spontaneous recovery, SR; non-spontaneous recovery, NSR: comprising transplantation or death) was defined by the status after 4 weeks post admission.

Assessment of prognosis

Serum sodium, KCC, MELD, UKELD and MELD-Na were assessed upon admission. Parameters were correlated with the outcome at 4 weeks after admission. In

order to calculate the individual MELD score we used the formula as published by Kamath *et al.* [21]. If the bilirubin and creatinine values were below 1.0 mg/dl they were set to 1.0 mg/dl. If the creatinine was above 4.0 mg/dl or the patients underwent dialysis during two weeks before assessment, the creatinine value was adjusted to 4.0 mg/dl. In order to calculate the individual MELD-Na score we used the formula as published by Ruf *et al.* [17]. If the sodium values were below 125 mmol/l they were set to 125 mmol/l, if the values were above 140 mmol/l they were adjusted to 140 mmol/l. In order to calculate the individual UKELD score we used the formula as published by Barber *et al.* [19]. The KCC were evaluated following published criteria. Differentiation between acetaminophen induced ALF and non-acetaminophen induced ALF have been made, as previously published [22]. Detailed formulas of the utilized scores are given in Table 2.

Statistics

Differences between parameters were evaluated by one-way Analysis of Variance, repeated-measure Analysis of Variance, or paired Student's t-test and t-test for independent samples t-test. For MELD and modified MELD statistics the Mann-Whitney test was used. For categorical variables, frequencies and percentages were estimated. χ^2 or Fisher's exact tests were used for categorical factors. ROC calculations were undertaken where applicable. Screening, optimal, and diagnostic cutoff values were calculated, and the optimal cutoff, including specificity and sensitivity as well as the AUC are shown in boxes included in the ROC plots. A $p < 0.05$ was considered statistically significant. All values are given as means \pm standard error of means. Analyses were performed with SPSS 19.0.1, version 2008 (SPSS, Chicago, IL, USA).

Results

Demographic data

Mean age of the 108 patients [69 (64%) females and 39 (36%) males] was 43.4 ± 16.2 . Underlying etiologies are presented in Figure 1A. Detailed laboratory parameters and general data are listed in Table 1. Sixty-two (60%) patients recovered spontaneously (SR), fifty-four (40%) deceased or underwent LTx (NSR) (Figure 1B). Differences concerning outcome in patients with non-acetaminophen induced ALF are presented in Table 3.

Sodium levels fail to predict outcome in ALF

To assess the predictive value on the clinical outcome of sodium in comparison to individual MELD parameters, we analyzed the individual parameters at the date of the maximum MELD score within 4 weeks after admission. Upon the point of maximum MELD, significant differences between SR and NSR groups were found for all of the

Table 1 Patient's general characteristics and laboratory parameter by outcome

	Reference ranges	Spontaneously recovered (SR) (n=65)	Not spontaneously recovered (NSR) (n=43)	Transplanted (LTx) (n=24)	Deceased (†) (n=19)	SR vs. NSR	SR vs. †	SR vs. LTx	LTx vs. †
Gender female (%)		38 (58%)	31 (72%)	17 (71%)	14 (73%)				
Age**		41 (64)	49 (61)	41.5 (48)	56 (54)	p<0.05	p<0.05	n.s.	p<0.05
BMI (kg/m²) **		23.37 (30.59)	26.64 (46.83)	25.91 (28.54)	27.7 (42.82)	n.s.	n.s.	n.s.	n.s.
PLATELETS [./nl]**	140-380	181 (350)	165 (450)	176.5 (450)	130 (325)	n.s.	n.s.	n.s.	n.s.
GGT [U/l]**	<55	113 (1102)	154 (1938)	154 (720)	158 (1938)	n.s.	n.s.	n.s.	n.s.
ALP [U/l]**	25-124	151 (3024)	183 (670)	173 (450)	214 (571)	n.s.	p<0.05	n.s.	n.s.
AST [U/l]**	<50	2329 (18650)	1081 (15388)	837 (4642)	2342 (15388)	n.s.	n.s.	p<0.05	n.s.
ALT [U/l]**	<50	2288 (12955)	1092 (7954)	946.5 (7177)	1682 (7835)	p<0.05	n.s.	p<0.05	n.s.
INR**	0.89-1.11	1.77 (2.96)	3.35 (8.36)	3.64 (7.88)	2.88 (8.17)	p<0.05	p<0.05	p<0.05	n.s.
Direct bilirubin [mg/dl]**	<0.2	5.8 (28.7)	13.8 (30)	18.25 (28)	9.3 (24.4)	p<0.05	n.s.	p<0.05	p<0.05
Total bilirubin [mg/dl]**	0.3-1.2	11.4 (40.5)	20.2 (43.1)	21.85 (37.7)	15.4 (38.9)	p<0.05	n.s.	p<0.05	p<0.05
Creatinine [mg/dl]**	0.6-1.3	0.99 (5.09)	1.81 (4.43)	1.385 (4.43)	2.5 (3.87)	p<0.05	p<0.05	p<0.05	p<0.05
Sodium [mmol/l]**	136-145	138 (24)	138 (27)	137.5 (23)	139 (27)	n.s.	n.s.	p<0.05	n.s.
MELD*		23.55 ± 0.66	36.37 ± 0.68	36.33 ± 0.8638	36.42 ± 1.12	p<0.05	p<0.05	p<0.05	n.s.
UKELD*		58.39 ± 0.57	65.12 ± 0.73	66.29 ± 0.8666	63.47 ± 1.20	p<0.05	p<0.05	p<0.05	n.s.
MELD-Na*		24.5 ± 0.65	36.49 ± 0.65	36.67 ± 0.81	36.24 ± 1.1	p<0.05	p<0.05	p<0.05	n.s.

*Mean ± Standard Error; *p<0.05 (Student's t-Test for unrelated groups; SPSS software, version).

**Median (Range); **p<0.05 (Mann-Whitney- U- Test; SPSS software).

Table 2 Model of end-stage liver disease (MELD) formula and sodium dependent modifications

Score	Formula
MELD	$MELD = 10 \left\{ \begin{array}{l} 0.957 \ln(\text{creatinine [mg/dl]}) \\ +0.378 \ln(\text{total bilirubin [mg/dl]}) \\ +1.12 \ln(\text{INR}) + 0.643 \end{array} \right\}$
MELDNa	$MELDNa = MELD - Na - [0.025 \times MELD \times (140 - Na)] + 140$ $(5.395 \times \ln(\text{INR}))$
UKELD	$UKELD = \left\{ \begin{array}{l} +(1.485 \times \ln(\text{creatinine } [\mu\text{mol/l}])) \\ +(3.13 \times \ln(\text{total bilirubin } [\mu\text{mol/l}])) \\ -(81.565 \times \ln(\text{Sodium [mmol/l]})) \end{array} \right\} + 435$

individual MELD parameters, including INR (SR 1.9 ± 0.08 , NSR 3.99 ± 0.32 , $p < 0.05$; Figure 2A), total bilirubin (SR: Median: 11.4 Range: 40.5 [mg/dl], NSR: Median: 20.2; Range: 43.1 Figure 2B) and creatinine (SR 1.32 ± 0.14 mg/dl, NSR 2.15 ± 0.19 mg/dl, $p < 0.05$; Figure 2C). In contrast to these findings, serum sodium did not show any difference between these two groups (SR 138.63 ± 0.57 mmol/l,

NSR 138.63 ± 0.99 mmol/l; Figure 2D). Analyses of the performance for the individual MELD parameters (Figure 3A) showed that increased INR at date of maximum MELD had a modest sensitivity and specificity (both 88%) (INR: cutoff: 2.47, AUC: 0.922; 95% CI: 0.867-0.977; $p < 0.05$). Increased creatinine alone had a sensitivity of 75% and a specificity of 70% at a cutoff value of 1.16 mg/dl (creatinine: AUC 0.723; 95% CI: 0.629-0.846; $p < 0.05$). In contrast, serum bilirubin lacked specificity at date of maximum MELD. However, a cutoff for serum bilirubin was calculated with an anticipated low specificity (bilirubin: cutoff: 19.8 mg/dl; AUC 0.661; 95% CI 0.54-0.774; $p < 0.05$). ROC curve analysis for serum sodium revealed no significant prognostic value.

Sodium based modifications fail to improve MELD in ALF
 The classical MELD score showed a strong correlation with the clinical outcome (Figure 3B: MELD: AUC




Table 3 Patient's general characteristics and laboratory parameter by outcome in cases of non-acetaminophen induced acute liver failure

		INR	Bilirubin [mg/dl]	Creatinine [mg/dl]	Sodium [mmol/l]	MELD	UKELD	MELD-Na
SR	N	50	50	50	49	50	49	49
	Mean	1.8	14.6	1.34	138.20	23.92	58.85	24.82
	Standart deviation	0.45	9.44	1.19	4.41	4.87	4.52	4.86
	Standar error	0.07	1.33	0.17	0.63	0.69	0.65	0.69
	Median	1.74	15.65	0.99	138.00	24.00	60	25
	Skewness	1.02	0.24	2.38	-0.202	-0.126	-0.714	-0.137
NSR	N	41	41	41	40	41	40	40
	Mean	3.98	20.8195	2.16	138.6	36.24	65.1	36.45
	Standart deviation	2.12	10.92050	1.22595	6.41233	4.53200	4.75988	4.19982
	Standard error	0.33	1.71	0.19	1.01	0.71	0.75	0.66
	Median	3.35	20.2	1.81	138	38	66	38
	Skewness	1.56	0.43	0.56	0.89	-0.79	-0.61	-0.92
Deceased	N	18	18	18	17	19	17	17
	Mean	4	16.67	2.53	140.29	36.22	63.47	36.24
	Standart deviation	2.292	10.53	1.23	7.48	4.93	4.96	4.53
	Standard error	0.54	2.48	0.29	1.81	1.16	1.20	1.1
	Median	3.12	14.85	2.45	139	39	63	38
	Skewness	1.451	0.859	0.221	0.555	-0.916	-0.194	-0.985
SR vs. NSR		P<0.01**	P<0.01*	P<0.01*	n.s. p=0.732	P<0.01*	P<0.01*	P<0.01*
SR vs. Deceased		P<0.01**	n.s.	P<0.01*	n.s. p=0.169	P<0.01*	P<0.01*	P<0.01*

*p<0.05 (Student's t-Test for unrelated groups; SPSS software, version).

**p<0.05 (Mann-Whitney-U-Test; SPSS software).

0.967; CI 0.935 – 0.998; $p < 0.01$). Since hyponatremia is associated with an unfavorable prognosis, inclusion of serum sodium into the MELD score was found to improve its predictive value in cirrhotic patients [13,17]. However, in our ALF cohort, the classical MELD was superior to sodium based modifications like the MELD-Na (AUC: 0.960; CI: 0.924-0.966; $p < 0.01$) or the UKELD (AUC: 0.828; CI: 0.738-0.918; $p < 0.01$).

MELD and MELD-Na are more sensitive than KCC in predicting NSR in non-acetaminophen induced ALF

A comparison of the MELD score, MELD-Na and the KCC in non-acetaminophen induced ALF demonstrated a better performance of the MELD based scores (Table 4). Concerning sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and overall diagnostic accuracy, the classic MELD was superior to KCC (MELD: Sensitivity: 0.90, Specificity: 0.92, PPV: 0.90, NPV: 0.92, diagnostic accuracy: 0.912; KCC: Sensitivity: 0.72, Specificity: 0.90, PPV: 0.86, NPV: 0.79, diagnostic accuracy: 0.818). While the accuracy of MELD-Na to predict outcome was lower, compared to classic MELD score, MELD-Na performed still better than KCC (MELD-

Na: Sensitivity: 0.90, Specificity: 0.90, PPV: 0.88, NPV: 0.92 and diagnostic accuracy: 0.898).

Prediction of lethal outcome for MELD and its sodium modifications depends on the extent of liver injury

A comparison of the MELD score at time of admission and the timepoint with a maximum MELD score within four weeks after admission in non-acetaminophen induced ALF revealed a better performance of the "maximum MELD" based scores (Table 4). Concerning sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and overall diagnostic accuracy the maximum MELD values were superior to the initial ones (initial MELD: AUC: 0.839; CI: 0.757-0.922; $p < 0.01$ Sensitivity: 0.78, Specificity: 0.76, PPV: 0.73, NPV: 0.81, diagnostic accuracy: 0.772, initial MELD-Na: AUC: 0.825; CI: 0.738-0.913, $p < 0.01$ Sensitivity: 0.80, Specificity: 0.76, PPV: 0.72, NPV: 0.83, diagnostic accuracy 0.780).

Discussion and conclusion

To our knowledge, this is the first study to evaluate a potential predictive role for serum sodium based MELD modifications in the clinical setting of ALF in a large prospective cohort. Compared to the individual MELD




Figure 2 Serum markers of liver damage and serum sodium in non-acetaminophen induced ALF. Standard serum parameters of liver injury were assessed during diagnostic procedures in ALF patients, to determine status and underlying etiology. Recordings are depicted for the day of maximum MELD score. (A) INR; (B) bilirubin; (C) creatinine; (D) sodium. All data are depicted as means \pm SEM. SR: spontaneous recovery, NSR: non-spontaneous recovery, *, p vs. NSR <0.05 .

parameters and in contrast to patients with chronic liver disease or post-transplant outcomes for acute liver failure [23], we could not find a clear association between serum sodium levels and clinical outcome in ALF which is in line with recent studies [24]. Accordingly, the serum sodium based MELD modifications MELD-Na and UKELD failed to improve the predictive value of the MELD in ALF patients. However, in our cohort the classic MELD as well as MELD-Na was superior to KCC in predicting outcome of ALF patients. Interestingly, hypernatremia was associated with lethal outcome in our ALF cohort. In contrast in chronic liver disease hyponatremia is associated with a worse outcome even for mid to long term survival [25], the rationale for utilizing UKELD and MELD-Na in cirrhosis.

Several studies have demonstrated a good specificity for KCC in ALF, however, the sensitivity to predict lethal outcome was modest in the vast majority of studies, especially in non-acetaminophen induced ALF [2,6,26]. Here, we found a fairly good specificity for KCC to predict NSR and as previously published only a modest sensitivity. Recent studies identified MELD as a prognostic tool with better sensitivity compared to KCC [21,27]. Specifically, in patients with non-acetaminophen induced ALF, MELD was superior

to KCC in predicting outcome [9]. This is in line with our findings, which show a better performance of MELD and MELD-Na compared to KCC in non-acetaminophen ALF.

MELD was primarily introduced as a prognostic tool for survival of patients with cirrhosis and portal hypertension following TIPS procedure [28]. Later, it was found to be useful in organ allocation for patients with chronic liver disease awaiting liver transplant and is therefore widely used in Western societies [21]. As hyponatremia is a common clinical problem in patients with end stage liver disease, especially in those individuals with portal hypertension, ascites and hepatorenal syndrome, sodium based modifications of the MELD have been introduced. In the UK, the UKELD is utilized instead of the MELD for organ allocation [19]. Murphy *et al.* identified hyponatremia as an independent risk factor for brain edema, a fatal complication of ALF [16,29]. Furthermore hyponatremia has been investigated extensively in the management of traumatic cerebral edema [30,31]

In our study we could not find an advantage of sodium based MELD modifications, compared to MELD or KCC in ALF. This is most likely due to the absence of ascites




Figure 3 ROC curves for single parameters of the MELD, sodium and different predictive scores in non-acetaminophen induced ALF. The prognostic value of single parameters comprising the classical MELD score was compared to serum sodium. The ROC curve shows the prognostic value of INR, creatinine, bilirubin and serum sodium at the point of maximum MELD during 4 weeks after admission (A). In addition the prognostic value of the classic MELD score was compared to sodium-based MELD modifications (UKELD and MELD-Na) and the INR as best single prognostic parameter as reference. Classical MELD provides the best performance of the given scores (B). Differences in the predictive value between the MELD and MELD-Na at the time of admission and at the time-point of its biggest dimension (C).

or hepatorenal syndrome in ALF, both common comorbidities of cirrhosis [32,33]. In our cohort, we did not find a difference in sodium levels between SR and NSR. Although Murphy *et al.* showed that patients with serum sodium between 145 and 150 mmol/l had fewer episodes of intracranial hypertension. There has been no difference in outcome [16]. Taken together we confirm previous publications, establishing MELD as a powerful prognostic tool for non-acetaminophen induced ALF patients.

Furthermore, our data revealed a crucial problem with the assessment of any prognostic factor. We found significant differences in its predictive value between the MELD at the time of admission and at the time-point of its biggest dimension. The maximum MELD performed best in predicting outcome in ALF, underlining the need for continuous clinical assessment of patients with ALF, given the heterogeneity and dynamic of this disease. However, this also shows the need for novel prognostic models and surrogate parameters for the degree of liver injury and disease progression [34]. While other possible MELD modifications might improve its accuracy in the future [12], sodium based MELD modifications are of little prognostic value in the clinical setting of ALF. Remien *et al.*, in contrast to other modifications of the KCC and MELD-Score,

Table 4 Comparison of the predictive values, sensitivity, specificity and diagnostic accuracy of the King’s College Criteria, MELD and MELD-Na at the date of maximum MELD during four weeks after admission and the MELD at date of admission

Score	Sensitivity	Specificity	PPV	NPV	Diagnostic accuracy
Maximum MELD	0.90	0.92	0.90	0.92	0.912
KCC	0.72	0.90	0.86	0.79	0.818
MELD-Na	0.90	0.90	0.88	0.92	0.898
Initial MELD	0,78	0,76	0.73	0.81	0.772
Initial MELD-Na	0,80	0,76	0,72	0,82	0,780

developed the MALD score which is novel as it builds upon the KCC by utilizing an understanding of the dynamics of hepatocyte damage following APAP overdose in the form of a dynamic mathematical model [35]. As ALF is a devastating clinical condition, it is worth it to evaluate new prognostic tools to improve outcome in this patients.

Abbreviations

ALF: Acute liver failure; KCC: Kings college criteria; MELD: Model of end-stage liver disease; Na: Sodium; NPV: Negative predictive value; NSR: No spontaneous remission; PPV: Positive predictive value; SR: Spontaneous remission; TIPS: Transjugular intrahepatic portosystemic shunt.

Competing interests

The authors declare that they have no competing interest.

Authors' contributions

PM participated in the study design, collected patient material, performed statistical analyses and drafted the manuscript. LPB collected patient material and revised the manuscript for important intellectual content. FT participated in the study design and revised the manuscript for important intellectual content. JPS performed statistical analyses and revised the manuscript for important intellectual content. MS performed detection of various serum parameters. JK collected patient material. CJ participated in the study design and coordination and collected patient material. AP participated in study coordination and collected patient material. FHS participated in study coordination and collected patient material. CT participated in the study design and revised the manuscript for important intellectual content. GG participated in study coordination and revised the manuscript for important intellectual content. AC conceived of the study, and participated in its design and coordination and revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by the Deutsche Forschungsgemeinschaft (DFG, grant CA267/6-1 and CA267/8-1), and the Wilhelm Laupitz Foundation to AC.

Author details

¹Department of Gastroenterology and Hepatology, University Hospital, University Duisburg-Essen, Hufelandstr 55, 45122, Essen, Germany.

²Department of Medicine III (Gastroenterology and Metabolic Disorders), University Hospital Aachen, Aachen, Germany. ³Department of General, Visceral and Transplantation Surgery, University Hospital, University Duisburg-Essen, Essen, Germany.

Received: 11 December 2012 Accepted: 21 March 2013

Published: 3 April 2013

References

1. Wigg AJ, Gunson BK, Mutimer DJ: **Outcomes following liver transplantation for seronegative acute liver failure: experience during a 12-year period with more than 100 patients.** *Liver Transpl* 2005, **11**:27-34.
2. Nguyen NTT, Vierling JM: **Acute liver failure.** *Curr Opin Organ Transplant* 2011, **16**:289-296.
3. Bernal W, Wendon J: **Liver transplantation in adults with acute liver failure.** *J Hepatol* 2004, **40**:192-197.
4. Burroughs AK, Sabin CA, Rolles K, Delvart V, Karam V, Buckles J, et al: **3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome.** *Lancet* 2006, **367**(9506):225-232.
5. Bernuau J, Goudeau A, Poinard T, Dubois F, Lesage G, Yvonne B, et al: **Multivariate analysis of prognostic factors in fulminant hepatitis B.** *Hepatology* 1986, **6**:648-651.
6. O'Grady JG, Alexander GJ, Hayllar KM, Williams R: **Early indicators of prognosis in fulminant hepatic failure.** *Gastroenterology* 1989, **97**:439-445.
7. Choi W-C, Arnaout WC, Villamil FG, Demetriou AA, Vierling JM: **Comparison of the applicability of two prognostic scoring systems in patients with fulminant hepatic failure.** *Korean J Intern Med* 2007, **22**:93-100.
8. Canbay A, Tacke F, Hadem J, Trautwein C, Gerken G, Manns MP: **Acute liver failure: a life-threatening disease.** *Dtsch Arztebl Int* 2011, **108**:714-720.
9. Yantorno SE, Kremers WK, Ruf AE, Trentadue JJ, Podestá LG, Villamil FG: **MELD is superior to King's college and Clichy's criteria to assess prognosis in fulminant hepatic failure.** *Liver Transpl* 2007, **13**:822-828.
10. Schmidt LE, Larsen FS: **MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury.** *Hepatology* 2007, **45**:789-796.
11. Perkins JD: **Another formula to determine the prognosis of patients with acute liver failure.** *Liver Transpl* 2009, **15**:986-991.
12. Bechmann LP, Jochum C, Kocabayoglu P, Sowa J-P, Kassalik M, Gieseler RK, et al: **Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury.** *J Hepatol* 2010, **53**:639-647.
13. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al: **Evidence-based incorporation of serum sodium concentration into MELD.** *Gastroenterology* 2006, **130**:1652-1660.
14. Häussinger D, Schless F: **Pathogenetic mechanisms of hepatic encephalopathy.** *Gut* 2008, **57**:1156-1165.
15. Badaut J, Lasbennes F, Magistretti PJ, Regli L: **Aquaporins in brain: distribution, physiology, and pathophysiology.** *J Cereb Blood Flow Metab* 2002, **22**:367-378.
16. Murphy N, Auzinger G, Bernal W, Wendon J: **The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure.** *Hepatology* 2004, **39**:464-470.
17. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG: **Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone.** *Liver Transpl* 2005, **11**:336-343.
18. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al: **Hyponatremia and mortality among patients on the liver-transplant waiting list.** *N Engl J Med* 2008, **359**:1018-1026.
19. Barber K, Pioli M, Blackwell J: **Development of a UK score for patients with end-stage liver disease.** *Hepatology* 2007, **46**:510A.
20. Hadem J, Tacke F, Bruns T, Langgartner J, Strnad P, Denk GU, et al: **Etiologies and outcomes of acute liver failure in Germany.** *Clin Gastroenterol Hepatol* 2012, **10**:664-669. e2.
21. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al: **A model to predict survival in patients with end-stage liver disease.** *Hepatology* 2001, **33**:464-470.
22. O'Grady JG, Gimson AE, O'Brien CJ, Pucknell A, Hughes RD, Williams R: **Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure.** *Gastroenterology* 1988, **94**:1186-1192.
23. Jin Y-J, Lim Y-S, Han S, Lee HC, Hwang S, Lee SG: **Predicting survival after living and deceased donor liver transplantation in adult patients with acute liver failure.** *J Gastroenterol* 2012, **47**:1115-1124.
24. Poddar B, Saigal S, Kumar A, Singh RK, Azim A, Gurjar M, et al: **Factors associated with outcome in acute liver failure in an intensive care unit.** *Indian J Gastroenterol* 2012. Epub ahead of print.
25. Vitale A, Bertacco A, Gambato M, D'Amico F, Morales RR, Frigo AC, et al: **Model for end-stage liver disease-sodium and survival benefit in liver transplantation.** *Transpl Int* 2013, **26**:138-144.
26. McPhail MJW, Wendon JA, Bernal W: **Meta-analysis of performance of King's College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure.** *J Hepatol* 2010, **53**:492-499.
27. Polson J: **Assessment of prognosis in acute liver failure.** *Semin Liver Dis* 2008, **28**:218-225.
28. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC: **A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.** *Hepatology* 2000, **31**:864-871.
29. Larsen FS, Wendon J: **Prevention and management of brain edema in patients with acute liver failure.** *Liver Transpl* 2008, **14**(Suppl 2):S90-96.
30. Rahman M, Friedman WA: **Hyponatremia in neurosurgical patients: clinical guidelines development.** *Neurosurgery* 2009, **65**:925-935. discussion 935-936.
31. Graziani G, Cucchiari D, Aroldi A, Angelini C, Gaetani P, Selmi C: **Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: when tolvaptan becomes a life saving drug.** *J Neurol Neurosurg Psychiatry* 2012, **83**:510-512.
32. Betrosian A-P, Agarwal B, Douzinas EE: **Acute renal dysfunction in liver diseases.** *World J Gastroenterol* 2007, **13**:5552-5559.
33. Vaa BE, Asrani SK, Dunn W, Kamath PS, Shah VH: **Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis.** *Mayo Clin Proc* 2011, **86**:37-42.

34. Samuel D, Ichai P: Prognosis indicator in acute liver failure: Is there a place for cell death markers? *J Hepatol* 2010, **53**:593-5.
35. Remien CH, Adler FR, Waddoups L, Box TD, Sussman NL: Mathematical modeling of liver injury and dysfunction after acetaminophen overdose: Early discrimination between survival and death. *Hepatology* 2012, **56**:727-734.

doi:10.1186/1471-230X-13-58

Cite this article as: Manka *et al.*: Serum sodium based modification of the MELD does not improve prediction of outcome in acute liver failure. *BMC Gastroenterology* 2013 **13**:58.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

